Patents by Inventor Samuel Jotham Reich

Samuel Jotham Reich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for siRNA inhibition of angiogenesis
    Patent number: 9150863
    Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 6, 2015
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Michael J. Tolentino, Samuel Jotham Reich
  • COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ANGIOGENESIS
    Publication number: 20150110861
    Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 23, 2015
    Inventors: Michael J. TOLENTINO, Samuel Jotham REICH
  • Compositions and methods for siRNA inhibition of angiogenesis
    Patent number: 8946403
    Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: February 3, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Michael J. Tolentino, Samuel Jotham Reich
  • COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ANGIOGENESIS
    Publication number: 20140056969
    Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Application
    Filed: September 30, 2013
    Publication date: February 27, 2014
    Inventors: Michael J. Tolentino, Samuel Jotham Reich
  • Compositions and methods for siRNA inhibition of angiogenesis
    Patent number: 8546345
    Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: October 1, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Michael J. Tolentino, Samuel Jotham Reich
  • Compositions and methods for siRNA inhibition of angiogenesis
    Patent number: 8541384
    Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve antiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: September 24, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Michael J. Tolentino, Samuel Jotham Reich
  • COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF HIF-1 ALPHA
    Publication number: 20120308645
    Abstract: RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.
    Type: Application
    Filed: July 23, 2012
    Publication date: December 6, 2012
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Samuel Jotham Reich, Enrico Maria Surace, Michael J. Tolentino
  • COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1
    Publication number: 20120276192
    Abstract: RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Application
    Filed: May 4, 2012
    Publication date: November 1, 2012
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Samuel Jotham Reich, Michael J. Tolentino
  • Compositions and methods for siRNA inhibition of HIF-1 ?
    Patent number: 8236775
    Abstract: RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: August 7, 2012
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Samuel Jotham Reich, Enrico Maria Surace, Michael J. Tolentino
  • COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2
    Publication number: 20120039986
    Abstract: RNA interference using small interfering RNAs which are specific for mRNA produced from the Ang1, Ang2 or Tie2 genes inhibits expression of these genes. Diseases which involve Ang1, Ang2 or Tie2 mediated angiogenesis, such as inflammatory and autoimmune diseases, diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Application
    Filed: June 20, 2011
    Publication date: February 16, 2012
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Samuel Jotham Reich, Michael J. Tolentino
  • Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2
    Patent number: 7994305
    Abstract: RNA interference using small interfering RNAs which are specific for mRNA produced from the Ang1, Ang2 or Tie2 genes inhibits expression of these genes. Diseases which involve Ang1, Ang2 or Tie2 mediated angiogenesis, such as inflammatory and autoimmune diseases, diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Grant
    Filed: April 19, 2004
    Date of Patent: August 9, 2011
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Samuel Jotham Reich, Michael J. Tolentino
  • SIRNA AND METHODS OF MANUFACTURE
    Publication number: 20110143400
    Abstract: Double-stranded RNA of about 19 to about 25 nucleotides in length capable of regulating gene expression by RNA interference is provided. Such double-stranded RNA are particularly useful for treating disease or conditions associated with a target mRNA or gene. Methods of manufacture and methods of use of the double-stranded RNA are also provided.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 16, 2011
    Applicant: OPKO OPHTHALMICS, LLC
    Inventors: Samuel Jotham Reich, N. Nicole Endejann
  • COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1
    Publication number: 20110092571
    Abstract: RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Application
    Filed: November 22, 2010
    Publication date: April 21, 2011
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Samuel Jotham Reich, Michael J. Tolentino
  • siRNA and methods of manufacture
    Patent number: 7872118
    Abstract: Double-stranded RNA of about 19 to about 25 nucleotides in length capable of regulating gene expression by RNA interference is provided. Such double-stranded RNA are particularly useful for treating disease or conditions associated with a target mRNA or gene. Methods of manufacture and methods of use of the double-stranded RNA are also provided.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: January 18, 2011
    Assignee: Opko Ophthalmics, LLC
    Inventors: Samuel Jotham Reich, N. Nicole Endejann
  • Compositions and methods for siRNA inhibition of angiogenesis
    Patent number: 7750143
    Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: July 6, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Michael J. Tolentino, Samuel Jotham Reich
  • COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF HIF-1 ALPHA
    Publication number: 20100136101
    Abstract: RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.
    Type: Application
    Filed: December 3, 2009
    Publication date: June 3, 2010
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Samuel Jotham Reich, Enrico Maria Surace, Michael J. Tolentino
  • Compositions and methods for siRNA inhibition of angiogenesis
    Patent number: 7674895
    Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: March 9, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Samuel Jotham Reich, Michael J. Tolentino
  • Compositions and methods for siRNA inhibition of HIF-1 alpha
    Patent number: 7645744
    Abstract: RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: January 12, 2010
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Samuel Jotham Reich, Enrico Maria Surace, Michael J. Tolentino
  • COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF HIF-1 ALPHA
    Publication number: 20090191263
    Abstract: RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.
    Type: Application
    Filed: January 26, 2009
    Publication date: July 30, 2009
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Samuel Jotham Reich, Enrico Maria Surace, Michael J. Tolentino
  • COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ANGIOGENESIS
    Publication number: 20090104259
    Abstract: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
    Type: Application
    Filed: December 4, 2008
    Publication date: April 23, 2009
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Michael J. Tolentino, Samuel Jotham Reich